Modafinil vs Dextroamphetamine for Narcolepsy and ADHD: Indications, Risks, and Regulation

For narcolepsy, both modafinil and dextroamphetamine are approved to improve wakefulness. For ADHD, dextroamphetamine is approved, while modafinil is not approved for routine treatment in adults. The key differences involve stimulant intensity, abuse risk classification, and safety considerations, especially cardiovascular effects.

Approved Uses

Modafinil is approved in adults to treat excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. It promotes wakefulness but does not treat cataplexy.

Dextroamphetamine is approved for narcolepsy and for attention deficit hyperactivity disorder. In ADHD, it improves attention, impulse control, and hyperactivity symptoms.

For narcolepsy, both medications may be considered. For ADHD, dextroamphetamine is an established treatment, while modafinil is not approved for adult use in this condition.

How They Work

Dextroamphetamine increases the release of dopamine and norepinephrine and reverses their transporters, producing a strong central stimulant effect.

Modafinil weakly inhibits dopamine reuptake and is also believed to influence orexin and histamine systems involved in wakefulness. Its effects promote alertness but are generally less classically stimulating than amphetamine.

Dextroamphetamine typically produces more pronounced stimulant effects. Modafinil is often described as promoting wakefulness without the same intensity of sympathetic stimulation.

Regulation and Abuse Risk

Dextroamphetamine is classified as a Schedule II controlled substance. This category reflects a recognized risk of abuse, dependence, and diversion.

Modafinil is classified as Schedule IV. It can produce psychoactive effects and carries abuse potential, but regulators consider its risk lower than amphetamine-based stimulants.

Schedule II medications are subject to stricter prescribing rules and tighter refill controls than Schedule IV drugs.

WordPress Tables

Dosing and Duration

Modafinil is typically taken once daily, most commonly 200 mg in the morning for narcolepsy or obstructive sleep apnea, or about one hour before a work shift for shift work disorder.

Dextroamphetamine dosing depends on formulation. Immediate-release forms are often taken multiple times per day, while extended-release formulations are taken once daily.

For many patients, dosing convenience is a practical difference. Modafinil’s once-daily schedule contrasts with the more variable dosing patterns of dextroamphetamine, depending on the product prescribed. Modafinil’s elimination half-life in healthy adults is approximately 15 hours.

Safety Considerations

Both medications can cause insomnia, anxiety, decreased appetite, and increased heart rate.

Dextroamphetamine carries established cardiovascular warnings, including increases in blood pressure and heart rate, and requires caution in patients with structural heart disease. It may exacerbate psychosis or mania in susceptible individuals.

Modafinil is generally well tolerated but has been associated with rare serious skin reactions, including Stevens-Johnson syndrome. It should be used cautiously in patients with certain cardiac conditions or psychiatric histories. It may reduce the effectiveness of hormonal contraceptives and requires dose reduction in severe hepatic impairment.

How Clinicians Choose Between Them

In narcolepsy, modafinil is commonly used as a first-line wakefulness-promoting agent. Dextroamphetamine may be considered when stronger stimulant effects are required or when other treatments are insufficient.

In ADHD, dextroamphetamine remains an approved and established therapy. Modafinil is not approved for adult ADHD treatment.

The choice depends on diagnosis, symptom profile, cardiovascular risk, psychiatric history, and tolerance of stimulant effects.

Sources

• Greenblatt, K., & Adams, N. (2023). Modafinil. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK531476/
• Patel, P., Marwaha, R., & Molla, M. (2025). Dextroamphetamine-Amphetamine. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK507808/
• U.S. Food and Drug Administration. (2015). PROVIGIL® (modafinil) tablets, for oral use, C-IV [Prescribing information]. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf